PMID: 476982May 1, 1979Paper

Propranolol, triiodothyronine, reverse triiodothyronine and thyroid disease

Clinical Endocrinology
J FeelyJ Crooks

Abstract

Propranolol alone was given to sixteen hyperthyroid, and concomitantly with thyroxine therapy to ten hypothyroid patients. Following treatment of the hyperthyroid group for 1-2 weeks there was a significant decrease in serum triiodothyronine (T3) which correlated with the plasma propranolol steady state concentration. The serum reverse T3 (rT3) rose significantly. Weight loss ceased in this group while weight gain occurred in patients who had a marked fall in serum T3. One patient with T3 toxicosis went into remission. The reduction in serum T3 was maintained in six patients receiving propranolol for more than 1 month. In the hypothyroid group the mean serum T3 level achieved with 0.15 mg thyroxine per day was significantly lower than in a control group who did not receive propranolol. In five patients following propranolol withdrawal there was a significant rise in T3, a fall in rT3 and TSH, and weight loss. Propranol may therefore have a clinically significant and direct action on the peripheral conversion of thyroxine to T3 and rT3.

References

May 1, 1977·The Journal of Clinical Endocrinology and Metabolism·R P VerhoevenM A Schalekamp
Jun 1, 1977·Clinical Endocrinology·G LottiA Masala
Jul 1, 1978·Clinical Endocrinology·J SaundersP H Sönksen
Apr 1, 1976·British Journal of Clinical Pharmacology·L E MurchisonW R Ferrier
Dec 1, 1975·The Journal of Clinical Endocrinology and Metabolism·I J ChopraD H Solomon
Nov 1, 1976·Clinical Endocrinology·W A RatcliffeJ G Ratcliffe
Jan 1, 1975·Metabolism: Clinical and Experimental·L P GeorgesJ J Canary
Jul 1, 1975·The Journal of Clinical Endocrinology and Metabolism·A G VagenakisL E Braverman
Nov 1, 1975·The Journal of Clinical Endocrinology and Metabolism·I J ChopraD H Solomon
May 3, 1976·Clinica Chimica Acta; International Journal of Clinical Chemistry·J SethW J Irvine
May 12, 1973·British Medical Journal·D G McLartyP Horton
Mar 19, 1966·Lancet·G Howitt, D J Rowlands
Jul 1, 1974·The Journal of Clinical Endocrinology and Metabolism·G I PortnayL E Braverman
Mar 13, 1971·British Medical Journal·R HallB J Ormston
Sep 1, 1968·Acta Medica Scandinavica·I Cullhed, A Parrow

❮ Previous
Next ❯

Citations

Jan 1, 1982·European Journal of Clinical Pharmacology·A AroH Sundquist
Oct 1, 1980·European Journal of Clinical Pharmacology·O R NilssonL Tegler
Jan 1, 1986·European Journal of Applied Physiology and Occupational Physiology·K Moriya
Dec 1, 1982·The American Journal of Medicine·D S CooperE C Ridgway
Mar 26, 1982·European Journal of Pharmacology·S P Baker, M J Katovich
Jan 1, 1991·Thyroid : Official Journal of the American Thyroid Association·W M Wiersinga
Jun 1, 1997·Thyroid : Official Journal of the American Thyroid Association·R E de la RosaJ R Tucci
Jul 1, 1981·Metabolism: Clinical and Experimental·K W Wenzel
Oct 1, 1981·Clinical Endocrinology·R J NormanS M Joubert
Jun 1, 1981·Clinical Endocrinology·M K JonesJ Birtwell
Jun 1, 1982·British Journal of Clinical Pharmacology·N R PedenJ Crooks
Sep 1, 1980·Clinical Endocrinology·J HowP D Bewsher
Dec 1, 1981·Clinical Endocrinology·S KaurI Ramsay
Feb 1, 1982·Journal of Clinical Pharmacology·J B ChambersA K Suda
Dec 1, 1981·British Journal of Clinical Pharmacology·G R JonesD Wynford-Thomas
Jul 5, 2003·The Annals of Pharmacotherapy·Darcie D Streetman, Ujjaini Khanderia
Apr 1, 1981·Postgraduate Medical Journal·M K JonesM Lewis
Mar 31, 2010·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Miguel A ArizaJoshua D Safer
Jan 1, 1981·Acta Medica Scandinavica·J KvetnyJ Date
Jan 1, 1982·Journal of Endocrinological Investigation·S RassuM Langer
Feb 1, 1981·Drug Intelligence & Clinical Pharmacy·T J Nester
Jan 1, 1983·Acta Medica Scandinavica. Supplementum·O R Nilsson, B E Karlberg
Sep 1, 1983·Scandinavian Journal of Clinical and Laboratory Investigation·G LindstedtA Svanborg

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.